GCLM and colorectal carcinoma: In this work, we reveal a nonmetabolic mechanism through which GCLM directly regulates nuclear factor kappa-B (NF-κB) activity, by interacting with NF-κB-repressing factor (NKRF), to endow CRC cells with resistance to platinum-based chemotherapy.